BRPI0712936B8 - processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas - Google Patents
processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidasInfo
- Publication number
- BRPI0712936B8 BRPI0712936B8 BRPI0712936A BRPI0712936A BRPI0712936B8 BR PI0712936 B8 BRPI0712936 B8 BR PI0712936B8 BR PI0712936 A BRPI0712936 A BR PI0712936A BR PI0712936 A BRPI0712936 A BR PI0712936A BR PI0712936 B8 BRPI0712936 B8 BR PI0712936B8
- Authority
- BR
- Brazil
- Prior art keywords
- propanamides
- fluorobenzyloxy
- benzylamino
- production
- less
- Prior art date
Links
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- -1 2-fluorobenzyloxy Chemical group 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002262 Schiff base Substances 0.000 abstract 1
- 150000004753 Schiff bases Chemical class 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000002585 base Substances 0.000 abstract 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000002638 heterogeneous catalyst Substances 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 abstract 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 abstract 1
- 229950002652 safinamide Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06012565 | 2006-06-19 | ||
| EP06012565.5 | 2006-06-19 | ||
| PCT/EP2007/005105 WO2007147491A1 (en) | 2006-06-19 | 2007-06-08 | Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0712936A2 BRPI0712936A2 (pt) | 2012-12-18 |
| BRPI0712936B1 BRPI0712936B1 (pt) | 2021-02-23 |
| BRPI0712936B8 true BRPI0712936B8 (pt) | 2021-05-25 |
Family
ID=37101658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0712936A BRPI0712936B8 (pt) | 2006-06-19 | 2007-06-08 | processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8076515B2 (enExample) |
| EP (2) | EP2029524B1 (enExample) |
| JP (2) | JP5240476B2 (enExample) |
| KR (2) | KR101410291B1 (enExample) |
| CN (2) | CN101472880B (enExample) |
| AR (1) | AR061510A1 (enExample) |
| AU (1) | AU2007263328C1 (enExample) |
| BR (1) | BRPI0712936B8 (enExample) |
| CA (1) | CA2653012C (enExample) |
| CY (2) | CY1115951T1 (enExample) |
| DK (2) | DK2029524T3 (enExample) |
| EA (2) | EA025326B1 (enExample) |
| ES (2) | ES2527437T3 (enExample) |
| HR (2) | HRP20150136T1 (enExample) |
| HU (1) | HUE030233T2 (enExample) |
| IL (1) | IL195294A (enExample) |
| LT (1) | LT2474521T (enExample) |
| MX (2) | MX342698B (enExample) |
| NO (2) | NO342018B1 (enExample) |
| NZ (2) | NZ595737A (enExample) |
| PL (2) | PL2029524T3 (enExample) |
| PT (2) | PT2474521T (enExample) |
| RS (2) | RS55464B1 (enExample) |
| SI (2) | SI2474521T1 (enExample) |
| TW (2) | TWI412512B (enExample) |
| WO (1) | WO2007147491A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1658062E (pt) * | 2003-08-25 | 2010-03-31 | Newron Pharm Spa | Derivados de alfa-amino amida úteis como agentes antiinflamatórios |
| EA025326B1 (ru) * | 2006-06-19 | 2016-12-30 | Ньюрон Фармасьютикалс С.П.А. | Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала |
| CN101896456B (zh) * | 2007-12-11 | 2014-10-22 | 纽朗制药有限公司 | 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法 |
| EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
| KR101851118B1 (ko) * | 2010-04-27 | 2018-04-23 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 랄핀아미드 메탄설포네이트 염들 또는 이들의 ｒ―에난티오머들의 제조 방법 |
| HK1209123A1 (en) | 2012-12-03 | 2016-03-24 | 霍夫曼-拉罗奇有限公司 | Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1) |
| WO2014178083A1 (en) | 2013-05-03 | 2014-11-06 | Council Of Scientific & Industrial Research | An improved synthesis of anti-parkinson agent |
| CN104292128A (zh) * | 2014-07-01 | 2015-01-21 | 南京正科制药有限公司 | 一种沙芬酰胺晶型a |
| JP6466109B2 (ja) * | 2014-09-09 | 2019-02-06 | 東ソー・ファインケム株式会社 | ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法 |
| CN105017060B (zh) * | 2015-07-03 | 2017-06-16 | 南京正大天晴制药有限公司 | 一种沙芬酰胺新晶型及其制备方法 |
| CN106365966A (zh) * | 2015-07-24 | 2017-02-01 | 上海医药集团股份有限公司 | 一种苄基芳基醚的制备方法 |
| CN105061245A (zh) * | 2015-08-25 | 2015-11-18 | 成都维恒医药科技有限公司 | 一种高纯度沙芬酰胺的制备方法 |
| CN106220525A (zh) * | 2016-07-31 | 2016-12-14 | 合肥远志医药科技开发有限公司 | 一种工业化沙芬酰胺甲磺酸盐的制备方法 |
| CN106336363B (zh) * | 2016-08-22 | 2018-10-30 | 上海医药集团股份有限公司 | 一种沙芬酰胺甲磺酸盐晶型c及其制备方法 |
| CN106565521B (zh) * | 2016-08-24 | 2019-03-08 | 浙江美诺华药物化学有限公司 | (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法 |
| CN106596828B (zh) * | 2016-12-15 | 2018-09-25 | 扬子江药业集团有限公司 | 一种甲磺酸沙芬酰胺有关物质的检测方法 |
| CN107271600B (zh) * | 2017-07-28 | 2019-01-25 | 成都百裕制药股份有限公司 | 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法 |
| CN107759487A (zh) * | 2017-11-23 | 2018-03-06 | 江苏恒盛药业有限公司 | 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法 |
| CN107857713A (zh) * | 2017-11-23 | 2018-03-30 | 江苏恒盛药业有限公司 | 一种沙芬酰胺氢溴酸盐及其一种晶型 |
| WO2019167085A1 (en) * | 2018-03-01 | 2019-09-06 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate |
| US11111208B2 (en) | 2019-06-17 | 2021-09-07 | RK Pharma Solutions LLC | Process for the preparation of safinamide mesylate intermediate |
| US11225457B2 (en) | 2019-08-06 | 2022-01-18 | Medichem, S.A. | Process for preparing safinamide |
| CN111122736B (zh) * | 2019-12-30 | 2021-03-12 | 北京鑫开元医药科技有限公司海南分公司 | 一种用于检测布瓦西坦中间体中对映异构体的方法 |
| CN113214097B (zh) * | 2020-01-21 | 2022-08-30 | 厦门大学 | 治疗阿尔茨海默病的化合物 |
| CN112028754A (zh) * | 2020-06-17 | 2020-12-04 | 浙江美诺华药物化学有限公司 | 一种甲磺酸沙芬酰胺中间体的制备方法 |
| CN114088830B (zh) * | 2021-11-10 | 2022-09-23 | 石家庄四药有限公司 | 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法 |
| CN116008439B (zh) * | 2023-02-20 | 2023-10-27 | 山东绿叶制药有限公司 | 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法 |
| WO2025022300A1 (en) | 2023-07-25 | 2025-01-30 | Intas Pharmaceuticals Ltd. | An orodispersible pharmaceutical solid dosage form of safinamide |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| IL151952A0 (en) | 2000-03-31 | 2003-04-10 | Euro Celtique Sa | Aminopyridine derivatives and pharmaceutical compositions containing the same |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| US20040213842A1 (en) * | 2003-01-30 | 2004-10-28 | Dynogen Pharmaceuticals, Inc. | Methods of treating gastrointestinal tract disorders using sodium channel modulators |
| JP2006515327A (ja) * | 2003-01-30 | 2006-05-25 | ダイノジェン ファーマシューティカルズ， インコーポレイテッド | ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法 |
| AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| TW200507850A (en) * | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| PT1658062E (pt) | 2003-08-25 | 2010-03-31 | Newron Pharm Spa | Derivados de alfa-amino amida úteis como agentes antiinflamatórios |
| EP1524267A1 (en) | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
| EP1557166A1 (en) * | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| KR101277520B1 (ko) | 2004-09-10 | 2013-06-21 | 뉴론 파마슈티칼즈 에스. 피. 에이. | （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물 |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| EA025326B1 (ru) * | 2006-06-19 | 2016-12-30 | Ньюрон Фармасьютикалс С.П.А. | Применение сафинамида и ралфинамида высокой степени чистоты для лечения заболеваний и болезненных состояний в условиях, не препятствующих активности цитохромов системы cyp450 и не проявляющих блокирующих свойств в отношении herg канала |
| CN101896456B (zh) | 2007-12-11 | 2014-10-22 | 纽朗制药有限公司 | 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法 |
| EA019529B1 (ru) | 2007-12-19 | 2014-04-30 | Ньюрон Фармасьютикалс С.П.А. | Альфа-аминоамидные производные, применяемые в лечении психиатрических расстройств |
-
2007
- 2007-06-08 EA EA201101308A patent/EA025326B1/ru unknown
- 2007-06-08 PL PL07764601T patent/PL2029524T3/pl unknown
- 2007-06-08 MX MX2012005094A patent/MX342698B/es unknown
- 2007-06-08 PT PT121630859T patent/PT2474521T/pt unknown
- 2007-06-08 EP EP07764601.6A patent/EP2029524B1/en active Active
- 2007-06-08 WO PCT/EP2007/005105 patent/WO2007147491A1/en not_active Ceased
- 2007-06-08 NZ NZ595737A patent/NZ595737A/xx unknown
- 2007-06-08 CN CN2007800228798A patent/CN101472880B/zh not_active Ceased
- 2007-06-08 PL PL12163085T patent/PL2474521T3/pl unknown
- 2007-06-08 AU AU2007263328A patent/AU2007263328C1/en active Active
- 2007-06-08 NZ NZ572798A patent/NZ572798A/en unknown
- 2007-06-08 EP EP12163085.9A patent/EP2474521B1/en active Active
- 2007-06-08 SI SI200731854A patent/SI2474521T1/sl unknown
- 2007-06-08 KR KR1020097001124A patent/KR101410291B1/ko active Active
- 2007-06-08 RS RS20160965A patent/RS55464B1/sr unknown
- 2007-06-08 CA CA2653012A patent/CA2653012C/en active Active
- 2007-06-08 HU HUE12163085A patent/HUE030233T2/en unknown
- 2007-06-08 ES ES07764601.6T patent/ES2527437T3/es active Active
- 2007-06-08 PT PT07764601T patent/PT2029524E/pt unknown
- 2007-06-08 DK DK07764601.6T patent/DK2029524T3/da active
- 2007-06-08 HR HRP20150136TT patent/HRP20150136T1/hr unknown
- 2007-06-08 KR KR20147003965A patent/KR101491541B1/ko active Active
- 2007-06-08 ES ES12163085.9T patent/ES2602069T3/es active Active
- 2007-06-08 BR BRPI0712936A patent/BRPI0712936B8/pt active IP Right Grant
- 2007-06-08 RS RS20150114A patent/RS53824B1/sr unknown
- 2007-06-08 MX MX2008015704A patent/MX2008015704A/es active IP Right Grant
- 2007-06-08 DK DK12163085.9T patent/DK2474521T3/en active
- 2007-06-08 CN CN201310142245.3A patent/CN103284984B/zh active Active
- 2007-06-08 JP JP2009515731A patent/JP5240476B2/ja active Active
- 2007-06-08 LT LTEP12163085.9T patent/LT2474521T/lt unknown
- 2007-06-08 SI SI200731603T patent/SI2029524T1/sl unknown
- 2007-06-08 EA EA200970028A patent/EA017123B1/ru unknown
- 2007-06-15 TW TW101148004A patent/TWI412512B/zh active
- 2007-06-15 TW TW096121879A patent/TWI393700B/zh active
- 2007-06-19 AR ARP070102674A patent/AR061510A1/es active IP Right Grant
-
2008
- 2008-11-13 IL IL195294A patent/IL195294A/en active Protection Beyond IP Right Term
- 2008-12-18 US US12/338,825 patent/US8076515B2/en active Active
-
2009
- 2009-01-14 NO NO20090231A patent/NO342018B1/no unknown
-
2011
- 2011-11-03 US US13/288,891 patent/US8278485B2/en active Active
-
2013
- 2013-01-10 JP JP2013002429A patent/JP5795342B2/ja active Active
-
2015
- 2015-01-23 CY CY20151100072T patent/CY1115951T1/el unknown
-
2016
- 2016-10-18 CY CY20161101038T patent/CY1118113T1/el unknown
- 2016-11-03 HR HRP20161456TT patent/HRP20161456T1/hr unknown
-
2017
- 2017-11-30 NO NO20171916A patent/NO342644B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0712936B8 (pt) | processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| EA201070719A1 (ru) | Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты | |
| CR7718A (es) | Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso | |
| BRPI0409227C1 (pt) | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) | |
| BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
| BRPI0514681A (pt) | derivados de pirimidina | |
| UY29791A1 (es) | Sales novedosas de lisina de derivados de acido 4-( (fenoxialquil)tio)-fenoxiacetico | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| CR8975A (es) | Proceso para la produccion de derivados de amina opticamente activos | |
| AR079152A1 (es) | Inhibidores de glucosilceramida sintasa | |
| BR112012027062B8 (pt) | composto, processo para a preparação de um composto e usos do mesmo | |
| BRPI0915592A2 (pt) | composto agonista do receptor de gpr119, processo para a preparação do composto, composição farmacêutica que o compreende, uso do mesmo e método para o tratamento ou profilaxia de diabetes mellitus do tipo ii | |
| MX375432B (es) | Inhibidores de la replicacion de los virus de la gripe. | |
| ECSP088414A (es) | Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| CL2003002762A1 (es) | Compuestos derivados de pirrolopirimidina o pirrolopiridina sustituidas por una amina ciclica, sus sales; composicion farmaceutica; y su uso para preparar un antagonista de los receptores de crf, para tratar enfermedades como depresion, ansiedad, alz | |
| CL2024000714A1 (es) | Compuestos espirocíclicos | |
| BR112012017845A2 (pt) | novo processo para produção de derivados de benzofenona | |
| AR092960A1 (es) | Procedimiento para preparar compuestos tienopirimidina | |
| BRPI0518898A2 (pt) | composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto | |
| BRPI0609703B8 (pt) | compostos de éster de ácido benzóico, composições, usos, e métodos relacionados aos mesmos | |
| DOP2024000239A (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| BRPI0909737A2 (pt) | compostos de pirrolidinila, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: NEWRON PHARMACEUTICALS S.P.A. (IT) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |